Orogen Royalties Inc

Orogen Royalties Inc logo
🇺🇸United States
Ownership
Public
Established
2020-01-01
Employees
10K
Market Cap
-
Website
http://www.organon.com
Introduction

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)

First Posted Date
2008-04-02
Last Posted Date
2022-02-17
Lead Sponsor
Organon and Co
Target Recruit Count
137
Registration Number
NCT00651404

An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-04-01
Last Posted Date
2022-02-03
Lead Sponsor
Organon and Co
Target Recruit Count
24
Registration Number
NCT00647933

4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-03-24
Last Posted Date
2022-02-02
Lead Sponsor
Organon and Co
Target Recruit Count
56
Registration Number
NCT00641771

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-03-14
Last Posted Date
2024-05-09
Lead Sponsor
Organon and Co
Target Recruit Count
46
Registration Number
NCT00636207

A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)

First Posted Date
2008-02-21
Last Posted Date
2022-02-04
Lead Sponsor
Organon and Co
Target Recruit Count
108
Registration Number
NCT00620464

A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)

Phase 3
Completed
Conditions
Interventions
First Posted Date
2008-02-21
Last Posted Date
2022-02-04
Lead Sponsor
Organon and Co
Target Recruit Count
301
Registration Number
NCT00620035

Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)

First Posted Date
2008-01-30
Last Posted Date
2024-04-19
Lead Sponsor
Organon and Co
Target Recruit Count
31
Registration Number
NCT00604812

An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma

First Posted Date
2008-01-23
Last Posted Date
2024-05-21
Lead Sponsor
Organon and Co
Target Recruit Count
51
Registration Number
NCT00599027
© Copyright 2024. All Rights Reserved by MedPath